Drug
Bcx9930 Monotherapy
Bcx9930 Monotherapy: highest development phase Phase 2, developed by BioCryst Pharmaceuticals. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- BioCryst Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| BCX9930 monotherapy NCT05116787 | Phase 2 | Paroxysmal Nocturnal Hemoglobinuria (PNH) |
Latest
No recent events.
Follow Bcx9930 Monotherapy on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.